Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 43 posted on June 7, 2023.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is  September 25, 2023, at 4:30 PM Eastern Time. The final full proposal submission deadline is September 25, 2023, at 4:30 PM Eastern Time for open areas of interest or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 42 posted on May 1, 2023.

• Updates to Area of Interest #7 Diagnostics
• Added new Area of Interest #14 Flexible and Strategic Therapeutics (FASTx)
• Added new Area of Interest #15 Next-generation COVID-19 Vaccines

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is extended to September 25, 2023, except for Area AOI 9.8, which has a deadline of May 17, 2023. The final full proposal submission deadline is extended to September 25, 2023 for open areas of interest except AOI 8.4 and AOI 9.8, which have a deadline of May 17, 2023 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 41 posted on April 17, 2023.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is May 17, 2023. The final full proposal submission deadline is May 17, 2023, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 40 posted on April 3, 2023.

• Added new AOI 8.4 COVID-19 Immune Assay(s) Development and Implementation, with a due date of May 3, 2023.
• Added new AOI 9.8 COVID-19 Monoclonal Antibody Therapeutics for Pre-Exposure Prophylaxis (PrEP), with a due date for White Papers of April 21, 2023.
• Added new AOI 9.9 COVID-19 Monoclonal Antibody Therapeutics for Treatment. Note that an initial Quad Chart/White Paper will not be sought for this area of interest. Offerors must submit Full Proposals in accordance with the instructions provided in Part VI Full Proposal Instructions of the BAA.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline extended to May 17, 2023, except for Area AOI 9.8, which has a deadline of April 21, 2023. The final full proposal submission deadline extended is May 17, 2023 for open areas of interest except AOI 8.4, which has a deadline of May 3, 2023 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 39 posted on Mar 14, 2023.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is extended to May 17, 2023. The final full proposal submission deadline is is extended to May 17, 2023,  or as specified in the invitation letter. 

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 38 posted on Mar3, 2023.

The purpose of this amendment is to provide responses to the questions received under Area of Interest (AOI) 9.7 “Implementation of Phase 2 Clinical Trial to Investigate Novel Host-directed Therapeutics Candidates to Treat Acute Respiratory Distress Syndrome (ARDS) [Open until March 14, 2023].”  A list of questions and answers is attached.

Additionally, an updated Transfer of Obligation Table under the Draft Protocol Synopsis is attached.  A summary of changes in the Transfer of Obligation Table is listed below:

• Deleted “diary” in 6.0 Data Management and “diaries” in 9.0 Medical Writing and Report Publishing Activities.
• Replaced “comparator,” “comparator agent,” or “comparator agents” with “placebo” or “placebos” in 2.4 Clinical Monitoring/Site Mgmt. (Lab Monitoring/Pharmacy/Unblinded Monitoring/Other) & 11.0 Other Outsourced Activities (Please Specify).

Lastly, this amendment provides the Small Business Subcontracting Plan Template as an attachment.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is Mar 17, 2023. The final full proposal submission deadline is Mar 17, 2023 for all AOIs except #9.7 or as specified in the invitation letter.  The deadline for AOI #9.7 is March 14, 2023. 

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is amendment 37 posted on Jan 13, 2023.

Note: addition of new Area of Interest: 9.7 Implementation of phase 2 clinical trial to investigate novel host-directed therapeutics candidates to treat acute respiratory distress syndrome (ARDS).

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is Mar 17, 2023. The final full proposal submission deadline is Mar 17, 2023 for all AOIs except #9.7 or as specified in the invitation letter.  The deadline for AOI #9.7 is March 14, 2023. 

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is Amendment 36 posted on Dec 14, 2022.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. All submissions in response to this BARDA BAA must be submitted to the BARDA Digital Resources (BDR) Portal (https://bdr.hhs.gov/) with additional process detail in the BAA.  Note, there are updates to the Stage 1 Quad Chart and White Paper and the Stage 2 Full Proposal process described in the BAA.

The final white paper submission deadline is Mar 17, 2023. The final full proposal submission deadline is Mar 17, 2023. or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA. 

The latest BARDA Broad Agency Announcement (BAA) is Amendment 35 posted on Nov15, 2022.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. All submissions in response to this BARDA BAA must be submitted to the BARDA Digital Resources (BDR) Portal (https://bdr.hhs.gov/) with additional process detail in the BAA.  Note, there are updates to the Stage 1 Quad Chart and White Paper and the Stage 2 Full Proposal process described in the BAA.

The final white paper submission deadline is Dec 15, 2022. The final full proposal submission deadline is Dec 15, 2022 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  

The latest BARDA Broad Agency Announcement (BAA) is Amendment 33, posted on July 14, 2022.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is Dec 15, 2022. The final full proposal submission deadline is Dec 15, 2022, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  

The latest BARDA Broad Agency Announcement (BAA) is Amendment 32, posted on May 2, 2022.

*Note: Amendment 32 only updates the SAM.GOV description to reflect the extended submission deadline of Dec 15, 2022. Please refer to the Changes Table from Amendment 31 to see change history.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is Dec 15, 2022. The final full proposal submission deadline is Dec 15, 2022, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  

The latest BARDA Broad Agency Announcement (BAA) is Amendment 30, posted on April 15, 2022.

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is May 2, 2022. The final full proposal submission deadline is May 2, 2022, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is Amendment 29, posted on Oct 26, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is May 2, 2022. The final full proposal submission deadline is May 2, 2022, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is Amendment 28, posted on Aug 2, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2021. The final full proposal submission deadline is October 31, 2021, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is Amendment 27, posted on June 29, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2021. The final full proposal submission deadline is October 31, 2021, or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19 or in response to the Special Instructions for Area of Interest #3.4, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 26 posted on June 3, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result) 
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA issued responses to inquiries received under Special Instructions Area of Interest #3.4 (Antibacterial Accelerator) and revised the Special Instructions. The Inquiries and Responses and revised Special Instructions are issued as detailed in the attached documents. Full proposal submissions for Special Instructions AOI #3.4 will be accepted through June 28, 2021. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline extended to October 31, 2021. The final full proposal submission deadline extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 25 posted on May 12, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result) 
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA added Special Instructions Area of Interest #3.4 (Antibacterial Accelerator). The attached Special Instructions are issued as detailed in the attached documents. Full proposal submissions for Special Instructions AOI #3.4 will be accepted through June 28, 2021. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline extended to October 31, 2021. The final full proposal submission deadline extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 24 posted on May 5, 2021.

Note: COVID-19 response related Areas of Interest include:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result) 
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended Area of Interest 9.2 COVID-19 Therapeutics. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline extended to October 31, 2021. The final full proposal submission deadline extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposal submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 23 posted on March 8, 2021.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
• AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
• AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
• AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result) 
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA revised, suspended, added sub-Area of Interest 7.7 Emerging Diseases Diagnostics and suspended AOI 12.2 Vaccine Production Platform. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline extended to October 31, 2021. The final full proposal submission deadline extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 22 posted on November 27, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA clarified the revised AOI 12.2 Vaccine Production Platform and white papers and full proposals will be accepted through February 28, 2021. BARDA suspended AOI 10 Respiratory Protective Devices and AOI 8.3 COVID-19 Vaccine. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is extended to October 31, 2021. The final full proposal submission deadline is extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 21 posted on November 24, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA revised AOI 12.2 Vaccine Production Platform and white papers and full proposals will be accepted through February 28, 2021. BARDA suspended AOI 10 Respiratory Protective Devices and AOI 8.3 COVID-19 Vaccine. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is extended to October 31, 2021. The final full proposal submission deadline is extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 20 posted on October 26, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 10 Respiratory Protective Devices and AOI 8.3 COVID-19 Vaccine. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is extended to October 31, 2021. The final full proposal submission deadline is extended to October 31, 2021 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 19 posted on August 17, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 10 Respiratory Protective Devices and AOI 8.3 COVID-19 Vaccine. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offerors should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 18 posted on July 24, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 10 Respiratory Protective Devices. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 18 posted on July 24, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• [NEW] AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 10 Respiratory Protective Devices. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 17 posted on June 3, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• [NEW] AOI 7.7.4 Diagnostic Assay for SARS-CoV-2 as part of FDA-cleared panel for influenza and other respiratory viruses using FDA-cleared platforms
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 10 Respiratory protective devices
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA suspended AOI 9.3 immunomodulators or therapeutics targeting lung repair, suspended AOI 9.5 Pre-exposure and post-exposure prophylaxis, suspended AOI 11 Ventilators, revised language for AOI 3 Antibacterials (submissions are placed in post COVID-19 review queue), added AOI 7.7.4, and revised language for AOI 9.2, 9.3, 9.5. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interest.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 16 posted on April 24, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), Including Serology Tests
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 9.3 Immunomodulators or therapeutics targeting lung repair
• AOI 9.5 Pre-exposure and post-exposure prophylaxis
• AOI 10 Respiratory protective devices
• AOI 11 Ventilators
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA clarified the language for rolling review of COVID-19 response related full proposals. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 15 posted on April 2, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 9.3 Immunomodulators or therapeutics targeting lung repair
• AOI 9.5 Pre-exposure and post-exposure prophylaxis
• AOI 10 Respiratory protective devices
• AOI 11 Ventilators
• AOI 17 Advanced Manufacturing Technologies

All contracting related inquiries should be sent to BARDA-BAA@hhs.gov. BARDA will conduct rolling reviews of COVID-19 response related full proposals only. BARDA will continuously review and expedite COVID-19 response related white papers and full proposals. Offeror should now also complete the Submission Data Integration Table.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

We appreciate your interest in partnering with BARDA.  Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue.  Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests.  BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement.  Thank you for understanding this unprecedented response and delays that will occur.

The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.

Note: COVID-19 response related Areas of Interest includes:

• AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
• AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
• AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
• AOI 8.3 COVID-19 Vaccine
• AOI 9.2 COVID-19 Therapeutics
• AOI 9.3 Immunomodulators or therapeutics targeting lung repair
• AOI 9.5 Pre-exposure and post-exposure prophylaxis
• AOI 10 Respiratory protective devices
• AOI 11 Ventilators
• AOI 17 Advanced Manufacturing Technologies

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.

The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest unitl further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 will be accepted. While we regret this action, it is required to focus BARDA's efforts on the immediate need. 

The latest BARDA BAA is amendment 13 posted on March 4, 2020.

All Areas of Interest are suspended except:

a. AOI 7.7.1 Diagnostic Assay for human coronavirus using existing FDA-cleared platforms,

b. AI 7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus

c. AOI 7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)

d. AOI 8.3 COVID-19 Vaccine,

e. AOI 9.2 COVID-19 Therapeutics,

f. AOI 9.3 Immunomodulators or therapeutics targeting lung repair, and

g. AOI 9.5 Pre-exposure and Post-exposure Prophylaxis,

h. AOI 10 Respiratory Protective Devices,

i. AOI 11 Ventilators. 

BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice.

The final white paper submission deadline is October 31, 2020. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter.